AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31285661 — intervention group
Group type: COMPARATOR
Intervention: No additional communication (Control)
Number of subjects: 1052
Study 28134628 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPUS, 20 min/d
Number of subjects: 5983
Study 26407963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat Soft Mist Inhaler
Number of subjects: 200
Study 26407963 — intervention group
Group type: COMPARATOR
Intervention: HandiHaler
Number of subjects: 200
Study 25194940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body strength + aerobic training (LBS-A)
Number of subjects: 51
Study 25194940 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body strength + aerobic training (UBS-A)
Number of subjects: 51
Study 25194940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor activities (GMA)
Number of subjects: 51
Study 22189843 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril plus amlodipine
Number of subjects: 1414
Study 22189843 — intervention group
Group type: COMPARATOR
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 1414
Study 19417602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography with preload
Number of subjects: 60
Study 19417602 — intervention group
Group type: COMPARATOR
Intervention: Acceleromyography without preload
Number of subjects: 60
Study 19417602 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of acceleromyographic TOF ratios
Number of subjects: 60
Study 19417602 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of both acceleromyography and mechanomyography
Number of subjects: 60
Study 19417602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography and mechanomyography
Number of subjects: 60
Study 17492896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Number of subjects: 0
Study 16388304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (VivaStyle)
Number of subjects: 6
Study 16388304 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% hydrogen peroxide (FKD)
Number of subjects: 6
Study 12075201 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium bicortical screws
Number of subjects: 40
Study 12075201 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable copolymer screws (poly‐L‐lactic acid 82% and polyglycolic acid 18%)
Number of subjects: 40
Study 10321858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic based interviews
Number of subjects: 210
Study 10321858 — intervention group
Group type: COMPARATOR
Intervention: Self completion at home
Number of subjects: 210
Study 8757422 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) at 375 mg and 250 mg b.i.d. for body weight > 60 and < or = 60 kg, respectively
Number of subjects: 159
Study 8757422 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (AZT) maintaining the current dosage
Number of subjects: 159
Study 8757422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AZT and ddI)
Number of subjects: 159
Study 8757422 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 159
Study 1914801 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (1674 J/day or 400 cal/day of lean meat, fish, or fowl)
Number of subjects: 33
Study 1914801 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet (4185-6277 J/day or 1000-1500 cal/day)
Number of subjects: 33
Study 6884233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyposensitization (1,750,000 PNU, 3,500,000 NU)
Number of subjects: 26
Study 6884233 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hyposensitization (1,550 PNU, 3,100 NU)
Number of subjects: 26
Study 6884233 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 31045817 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal technique/endoscopic surgery (BG)
Number of subjects: 70
Study 31045817 — intervention group
Group type: COMPARATOR
Intervention: Microscopic surgery (OG)
Number of subjects: 70
Study 28542506 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Cash (DC)
Number of subjects: 3584
Study 28542506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Food Voucher (FFV)
Number of subjects: 3584
Study 28542506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Cash (SC)
Number of subjects: 3584
Study 25606785 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH, 20 IU/kg/dose)
Number of subjects: 20
Study 25606785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25606785 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH)
Number of subjects: 20
Study 25606785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 23744509 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of HAV/MMRV/PCV-7 (Group 1)
Number of subjects: 653
Study 23744509 — intervention group
Group type: COMPARATOR
Intervention: Non-concomitant administration of HAV (Group 2)
Number of subjects: 653
Study 21841997 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocancellous porcine bone graft
Number of subjects: 15
Study 21841997 — intervention group
Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study 19196110 — intervention group
Group type: EXPERIMENTAL
Intervention: Real phototherapy (3 J/cm(‐2))
Number of subjects: 20
Study 19196110 — intervention group
Group type: COMPARATOR
Intervention: Placebo phototherapy (<.03 J/cm(‐3))
Number of subjects: 20
Study 19196110 — intervention group
Group type: COMPARATOR
Intervention: Control group (cleaned and dressed with 1% silver sulfadiazine without phototherapy)
Number of subjects: 20
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidex
Number of subjects: 60
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Duceram LFC
Number of subjects: 60
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Artglass
Number of subjects: 60
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Targis
Number of subjects: 60
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical regions
Number of subjects: 60
Study 17598135 — intervention group
Group type: EXPERIMENTAL
Intervention: Isthmus floor regions
Number of subjects: 60
Study 15154663 — intervention group
Group type: EXPERIMENTAL
Intervention: PS76A2 (10, 30, or 70 ng mistletoe lectin per ml)
Number of subjects: 272
Study 15154663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 11243947 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, twice daily)
Number of subjects: 911
Study 11243947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 911
Study 9842405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 60
Study 9842405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8092863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 35
Study 8092863 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study 2525460 — intervention group
Group type: EXPERIMENTAL
Intervention: Turret nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Number of subjects: 8
Study 2525460 — intervention group
Group type: COMPARATOR
Intervention: Inspiron nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Number of subjects: 8
Study 2525460 — intervention group
Group type: EXPERIMENTAL
Intervention: Turret nebulizer with ipratropium bromide (50, 50, 100, 200 micrograms)
Number of subjects: 8
Study 2525460 — intervention group
Group type: COMPARATOR
Intervention: Inspiron nebulizer with ipratropium bromide (50, 50, 100, 200 micrograms)
Number of subjects: 8
Study 2525460 — intervention group
Group type: EXPERIMENTAL
Intervention: Turret nebulizer
Number of subjects: 8
Study 2525460 — intervention group
Group type: COMPARATOR
Intervention: Inspiron nebulizer
Number of subjects: 8
Study 31313243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 14
Study 31573612 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab
Number of subjects: 1187
Study 31573612 — intervention group
Group type: COMPARATOR
Intervention: Doublets/bevacizumab
Number of subjects: 1187
Study 28532872 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaStretch
Number of subjects: 29
Study 28532872 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Land Based Stretching (LBS)
Number of subjects: 29
Study 28532872 — intervention group
Group type: COMPARATOR
Intervention: Control (normal physical activity)
Number of subjects: 29
Study 25176615 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily
Number of subjects: 379
Study 25176615 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily combined with tenofovir 300 mg
Number of subjects: 379
Study 25176615 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 379
Study 25176615 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-positive patients
Number of subjects: 379
Study 25176615 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-negative patients
Number of subjects: 379
Study 23350833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine (4 mg, with potential increase to 8 mg at week 4 or 8)
Number of subjects: 794
Study 23350833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 794
Study 23350833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study 23350833 — intervention group
Group type: COMPARATOR
Intervention: Fesoterodine and Placebo
Number of subjects: 794
Study 21362359 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (intervention group, n = 30)
Number of subjects: 61
Study 21362359 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 61
Study 20090354 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) interventions
Number of subjects: 0
Study 20090354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 20090354 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing
Number of subjects: 0
Study 16753387 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet (1,000 mg daily)
Number of subjects: 10
Study 16753387 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet (400 mg daily)
Number of subjects: 10
Study 14749743 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderberry juice (400 mg spray-dried powder containing 10% anthocyanes t.i.d. equivalent to 5 ml elderberry juice for 2 weeks)
Number of subjects: 40
Study 14749743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 14749743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of elderberry juice (50 ml) along with a high-fat breakfast
Number of subjects: 40
Study 11166743 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chorionic plate inflammation present in preterm deliveries (35.5%)
Number of subjects: 82
Study 11166743 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniochorionic‐decidual inflammation grades in preterm group: 31% severe (Grade 3‐4), 38% mild (Grade 1‐2), 31% none
Number of subjects: 82
Study 11166743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic bacteria isolated from patients with severe chorionic plate and/or chorioamnionic inflammation
Number of subjects: 82
Study 9274279 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pad variant 1
Number of subjects: 20
Study 9274279 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pad variant 2
Number of subjects: 20
Study 9274279 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pad variant 3
Number of subjects: 20
Study 9274279 — intervention group
Group type: COMPARATOR
Intervention: Control (previous pad variant)
Number of subjects: 20
Study 7930250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treadmill testing with planar thallium-201 scintigraphy
Number of subjects: 936
Study 7930250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 936
Study 7930250 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium perfusion imaging
Number of subjects: 936
Study 7930250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test with or without thallium
Number of subjects: 936
Study 2782945 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 (P2)
Number of subjects: 40
Study 2782945 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 (P3)
Number of subjects: 40
Study 2782945 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) (P1)
Number of subjects: 40
Study 55029 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin prophylaxis
Number of subjects: 112
Study 55029 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 112
Study 55029 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 112
Study 55029 — intervention group
Group type: COMPARATOR
Intervention: Sodium and calcium heparin administered subcutaneously
Number of subjects: 112
Study 28768700 — intervention group
Group type: EXPERIMENTAL
Intervention: Telematics support through Google Glass (GG) from an expert physician
Number of subjects: 72
Study 28768700 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no assistance
Number of subjects: 72
Study 26305649 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g)
Number of subjects: 3741
Study 26305649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (10 mg)/zeaxanthin (2 mg)
Number of subjects: 3741
Study 26305649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no LCPUFAs)
Number of subjects: 3741
Study 26305649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no lutein/zeaxanthin)
Number of subjects: 3741
Study 23442574 — intervention group
Group type: EXPERIMENTAL
Intervention: Online only group
Number of subjects: 180
Study 23442574 — intervention group
Group type: EXPERIMENTAL
Intervention: Online and face-to-face group
Number of subjects: 180
Study 23442574 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 180
Study 22054797 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg once daily)
Number of subjects: 308
Study 22054797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 19553452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation with physostigmine
Number of subjects: 22
Study 19553452 — intervention group
Group type: COMPARATOR
Intervention: Placebo with saline
Number of subjects: 22
Study 17976095 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to pulmonary artery shunt (RV-PA)
Number of subjects: 82
Study 17976095 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt (BTS)
Number of subjects: 82
Study 17976095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BTS and RV-PA)
Number of subjects: 82
Study 14998068 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 4499
Study 14998068 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 4499
Study 14998068 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan 10 mg
Number of subjects: 4499
Study 14998068 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 4499
Study 14998068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4499
Study 10997497 — intervention group
Group type: EXPERIMENTAL
Intervention: Penciclovir 1% cream applied 5 times daily for up to 7 days
Number of subjects: 205
Study 10997497 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 3% cream
Number of subjects: 205
Study 9115549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative isometry measurements (group I)
Number of subjects: 94
Study 9115549 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative isometry measurements (group II)
Number of subjects: 94
Study 9115549 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall failure rate in group I
Number of subjects: 94
Study 9115549 — intervention group
Group type: COMPARATOR
Intervention: Overall failure rate in group II
Number of subjects: 94
Study 1484177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day for 8 weeks)
Number of subjects: 412
Study 1484177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50, 100, or 200 mg/day for 12 weeks)
Number of subjects: 412
Study 1484177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 6382103 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 1,500 mg daily for 3 months
Number of subjects: 50
Study 6382103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31250356 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout supplementation (15 capsules daily containing 90 mg sulforaphane and 180 mg glucoraphanin)
Number of subjects: 40
Study 31250356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methylcellulose)
Number of subjects: 40
Study 31250356 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout supplementation
Number of subjects: 40
Study 30439359 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC + E2 (700μg)
Number of subjects: 439
Study 30439359 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC + E2 (900μg)
Number of subjects: 439
Study 30439359 — intervention group
Group type: EXPERIMENTAL
Intervention: ENG + E2 (100μg)
Number of subjects: 439
Study 30439359 — intervention group
Group type: EXPERIMENTAL
Intervention: ENG + E2 (125μg)
Number of subjects: 439
Study 30439359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 28476266 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 432
Study 28476266 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 432
Study 27340991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injections (16 mg/mL)
Number of subjects: 24
Study 27340991 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 24
Study 25403207 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended rituximab exposure (375 mg/m²) with 6×R‐CHOP‐14 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone on a 14-day schedule)
Number of subjects: 189
Study 25403207 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended rituximab exposure in poor-prognosis patients
Number of subjects: 189
Study 25403207 — intervention group
Group type: COMPARATOR
Intervention: RICOVER-60 trial (control group with 6×R‐CHOP‐14 plus eight 2-week applications of rituximab)
Number of subjects: 189
Study 25403207 — intervention group
Group type: COMPARATOR
Intervention: Comparison of outcomes between SMARTE-R-CHOP-14 and RICOVER-60
Number of subjects: 189
Study 22522725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n = 24)
Number of subjects: 683
Study 22522725 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 22)
Number of subjects: 683
Study 19244175 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 microg)
Number of subjects: 39
Study 19244175 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 39
Study 19244175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Selenium and Vitamin E
Number of subjects: 39
Study 19244175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19244175 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 39
Study 17346324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative education and telephone interview on the second postoperative day
Number of subjects: 234
Study 17346324 — intervention group
Group type: COMPARATOR
Intervention: Usual routine information (Control)
Number of subjects: 234
Study 15115902 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of bimakalim (0.1, 0.3 or 0.6 mg)
Number of subjects: 86
Study 15115902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of bimakalim (0.025 or 0.05 mg)
Number of subjects: 86
Study 15115902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimakalim (both high and low doses)
Number of subjects: 86
Study 15115902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 11641896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol consumption (1 gram per kg of body weight)
Number of subjects: 29
Study 11641896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethanol consumption)
Number of subjects: 29
Study 9853633 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model (consultation focused on selected high-risk ambulatory care patients)
Number of subjects: 6000
Study 9853633 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model
Number of subjects: 6000
Study 9853633 — intervention group
Group type: EXPERIMENTAL
Intervention: State model (consultation about new or changed prescriptions)
Number of subjects: 6000
Study 9853633 — intervention group
Group type: COMPARATOR
Intervention: Control model
Number of subjects: 6000
Study 7865090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% triclosan
Number of subjects: 8
Study 7865090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 8
Study 7865090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triclosan with 1.5% SLS
Number of subjects: 8
Study 7865090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% triclosan with 0.25% SLS
Number of subjects: 8
Study 7865090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan (topical application)
Number of subjects: 8
Study 2573298 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol high dose (0.01 mg/inhalation, two inhalations, three times daily)
Number of subjects: 210
Study 2573298 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol low dose (0.01 mg/inhalation, one inhalation, three times daily)
Number of subjects: 210